Skip to content
Screener

Ionis Pharmaceuticals IONS Interest expense and penalties, net (benefit)/charge recognized

Interest expense and penalties, net (benefit)/charge recognized at other companies

RBC Bearings logo
RBC BearingsRBC
$125K+66.7%
McCormick & Company, Incorporated logo
McCormick & Company, IncorporatedMKC
-$200K+11.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$25K0.0%
Ashland logo
AshlandASH
$1M+33.3%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$0
Essential Utilities logo
Essential UtilitiesWTRG
$18.75K-65.3%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.06B+39.6%
Enterprise value$8.97B+28.4%
P/S10.4×+3.5×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense.

The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 4:25 PM EST
Fiscal year
FY2026
Accession
0000874015-26-000115

We recognize interest and/or penalties related to income tax matters in income tax expense. During the years ended December 31, 2025, 2024 and 2023, we recognized $0.1 million, $0.1 million and $0.1 million, respectively, of accrued interest and penalties related to gross unrecognized tax benefits.

Item 15. Exhibits and Financial Statement Schedules

FAQ

What is Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized?
Ionis Pharmaceuticals (IONS) reported interest expense and penalties, net (benefit)/charge recognized of $25K in Q4 2025.
How has Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized changed year-over-year?
Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized decreased by 0.0% year-over-year, from $25K to $25K.
What is the long-term trend for Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized?
Over 2 years (2023 to 2025), Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized has grown at a 0.0% compound annual growth rate (CAGR), from $100K to $100K.
What does interest expense and penalties, net (benefit)/charge recognized mean?
The amount of interest and penalties accrued or recognized related to unrecognized tax benefits. This reflects the potential cost of non-compliance or aggressive tax positioning beyond the base tax liability.

Ask your AI about Ionis Pharmaceuticals's interest expense and penalties, net (benefit)/charge recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude